-+ 0.00%
-+ 0.00%
-+ 0.00%

Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients

Benzinga·01/13/2026 12:08:38
Listen to the news

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):

  • Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the study. 
  • The Company plans to present data in the second half of 2026, including available efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas. The planned data release is also expected to include safety, tolerability and pharmacokinetic (PK) data.

Ongoing Phase 1 clinical trial in advanced cancer patients (NCT06299839):

  • Pasithea expects to present longer-term follow-up data from patients in Cohort 4 (15mg capsule) through Cohort 8 (45mg capsule) in the second quarter of 2026.